Samuel  C. Blackman
Samuel C. Blackman
Senior Vice President, Silverback Therapeutics
Adresse e-mail validée de silverbacktx.com
Titre
Citée par
Citée par
Année
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ...
The Lancet 379 (9829), 1893-1901, 2012
8602012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors
I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ...
Journal of clinical oncology 30 (19), 2307-2313, 2012
2712012
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
GS Falchook, JC Trent, MC Heinrich, C Beadling, J Patterson, CC Bastida, ...
Oncotarget 4 (2), 310, 2013
1252013
Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates
B Wittels, B Glosten, EAM Faure, AH Moawad, M Ismail, J Hibbard, ...
Anesthesia & Analgesia 85 (3), 600-606, 1997
1191997
Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: Maternal outcomes.
B Wittels, B Glosten, EA Faure, AH Moawad, M Ismail, J Hibbard, ...
Anesthesia and analgesia 77 (5), 925-932, 1993
581993
The identification and characterization of oligodendrocyte thromboxane A2 receptors
SC Blackman, G Dawson, K Antonakis, GC Le Breton
Journal of Biological Chemistry 273 (1), 475-483, 1998
521998
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
GS Falchook, GV Long, R Kurzrock, KB Kim, HT Arkenau, MP Brown, ...
Clinical Cancer Research 20 (17), 4449-4458, 2014
492014
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation‐positive tumors
D Ouellet, KF Grossmann, G Limentani, N Nebot, K Lan, L Knowles, ...
Journal of pharmaceutical sciences 102 (9), 3100-3109, 2013
472013
Identification and functional characterization of thromboxane A2 receptors in Schwann cells
N Muja, SC Blackman, GC Le Breton, GH DeVries
Journal of neurochemistry 78 (3), 446-456, 2001
422001
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic …
DA Bershas, D Ouellet, DB Mamaril-Fishman, N Nebot, SW Carson, ...
Drug Metabolism and Disposition 41 (12), 2215-2224, 2013
412013
Toxicology screening in adolescent trauma.
S Gordon, WC Toepper, SC Blackman
Pediatric emergency care 12 (1), 36-39, 1996
381996
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation‐positive solid tumors
CL Denton, E Minthorn, SW Carson, GC Young, LE Richards‐Peterson, ...
The Journal of Clinical Pharmacology 53 (9), 955-961, 2013
332013
Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency
SC Blackman, NS Lurain, DP Witte, AH Filipovich, P Groen, MR Schleiss
Journal of pediatric hematology/oncology 26 (9), 601-605, 2004
312004
Assessment of the drug interaction potential and single‐and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib
AB Suttle, KF Grossmann, D Ouellet, LE Richards‐Peterson, G Aktan, ...
The Journal of Clinical Pharmacology 55 (4), 392-400, 2015
282015
Forehead swelling caused by Pott's puffy tumor in a 9‐year‐old boy with sinusitis
SC Blackman, MR Schleiss
Pediatrics international 47 (6), 704-707, 2005
282005
Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature
SC Blackman, AR Evenson, SD Voss, CE Barnewolt, M Puder
Fetal diagnosis and therapy 24 (2), 119-125, 2008
212008
Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
A Biondo, TA Yap, L Yan, A Patnaik, I Fearen, RD Baird, ...
Journal of Clinical Oncology 29 (15_suppl), 3037-3037, 2011
172011
Accelerating pediatric cancer drug development: challenges and opportunities for pediatric master protocols
T Khan, M Stewart, S Blackman, R Rousseau, M Donoghue, K Cohen, ...
Therapeutic innovation & regulatory science 53 (2), 270-278, 2019
152019
RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers
GS Falchook, GV Long, R Kurzrock, KB Kim, HT Arkenau, MP Brown, ...
Lancet 379 (9829), 1893, 2012
132012
Hematologic emergencies: acute anemia
SC Blackman, JAG del Rey
Clinical pediatric emergency medicine 6 (3), 124-137, 2005
132005
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20